Sacituzumab Tirumotecan Plus Immunotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

by | Jul 7, 2026 | Clinical Trials | 0 comments

​ Conditions: Recurrent or Metastatic Head and Neck Carcinoma

Interventions: Drug: Sacituzumab Tirumotecan Plus Immune Checkpoint Inhibitor

Sponsors: Biying Chen

Not yet recruiting Conditions: Recurrent or Metastatic Head and Neck Carcinoma
Interventions: Drug: Sacituzumab Tirumotecan Plus Immune Checkpoint Inhibitor
Sponsors: Biying Chen
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *